The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020

Abstract

Summary: No antiviral has been shown to reduce mortality in SARS-COV-2 patients to date. In the present observational and retrospective report, 3,099 patients with a definitive or highly probable diagnosis of infection due to COVID-19 were evaluated between May 1st to August 10th, 2020, at Centro Medico Bournigal (CMBO) and Centro Medico Punta Cana (CMPC), and all received compassionate treatment with Ivermectin. A total of 2,706 (87.3%) were discharged for outpatient treatment, all with mild severity of the infection. In 2,688 (99.33%) with outpatient treatment, the disease did not progress to warrant further hospitalization and there were no deaths. In 16 (0.59%) with outpatient treatment, it was necessary their subsequent hospitalization to a room without any death. In 2 (0.08%) with outpatient treatment, it was necessary their admission to the Intensive Care Unit (ICU) and 1 (0.04%) patient died. There were 411 (13.3%) patients hospitalized, being admitted at a COVID-19 room with a moderate disease 300 (9.7%) patients of which 3 (1%) died; and with a severe to critical disease were hospitalized in the ICU 111 (3.6%), 34 (30.6%) of whom died. The mortality percentage of patients admitted to the ICU of 30.6%, is similar with the percentage found in the literature of 30.9%. Total mortality was 37 (1.2%) patients, which is much lower than that reported in world statistics, which are around 3%.

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

“…Remarkably, only 16 of the 2688 patients (0.59%) required subsequent hospitalization with only a single death recorded. 61 …”

“… 40 – 45 Ivermectin hastens recovery and prevents deterioration in patients with mild to moderate disease treated early after symptoms. 45 , 49 – 52 , 61 , 62 Ivermectin hastens recovery and avoidance of ICU admission and death in hospitalized patients. 45 , 51 , 53 , 63 – 66 Ivermectin reduces mortality in critically ill patients with COVID-19.…”

“…Ivermectin hastens recovery and prevents deterioration in patients with mild to moderate disease treated early after symptoms. 45 , 49 – 52 , 61 , 62…”

Retrospective cohort study of Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in Healthcare Workers

“…In the present study, when comparing healthcare personnel who presented COVID-19 infection, the progression of the disease, the appearance of complications, the need for hospitalization and the occurrence of death, the difference between both groups was not statistically significant. These findings could be due to their average young age of 35 years, where patients tend to have fewer complications with COVID-19 infections and that the patients of both groups, were offered early treatment with Ivermectin, which diminishes the progression of SARS-CoV-2 infection, as seen in previous studies (1).…”

Ivermectin in the treatment of COVID-19- friend or foe?

“…At least eight of these seem to have been completed to date, and the forthcoming publication of the relevant study results is being eagerly anticipated. [43][44][45][46][47][48][49][50][51][52][53][54][55][56]58…”